Core Viewpoint - The recent surge in the stock price of Precision Medicine-B (02675) is attributed to the announcement of a national pricing guideline for surgical robots and related medical services, marking a significant turning point for the commercialization of the surgical robot industry [1] Group 1: Company Overview - Precision Medicine is recognized as one of the top two domestic surgical robot manufacturers in China, with rapid growth in multi-port, single-port, and natural orifice robots both domestically and internationally [1] - The company is expected to lead in the number of successful bids for domestic laparoscopic robot procurement by 2025 [1] Group 2: Industry Developments - The National Healthcare Security Administration has released a guideline that establishes a unified pricing framework for surgical robots, energy devices, and remote surgery, which is seen as a crucial development for the industry [1] - The remote surgical procedures are anticipated to receive approval from the National Medical Products Administration (NMPA) by November 2025, with a target of achieving 500 surgeries by October 2025 [1]